Efficacy Of Intravitreal Ranibizumab And Conbercept For The Treatment Of Macular Edema Secondary To Macular Branch Retinal Vien Occlusion

Objective:To observe and compare the therapeutic of intravitreal injection of conbercept and ranibizumab for the treatment macular edema secondary to macular branch retinal vein occlusion.Methods:Received intravitreal injection of ranibizumab 0.5mg/0.05 ml.After an initial.The study was a retrospective non-randomized clinical study.From June 2018 to October 2019,42 eyes were included in the second hospital of Hebei medical university.Forty-two patients with macular edema(ME)secondary to macular branch retinal vein occlusion(MBRVO)diagnosed by fundus examination,fundus fluorescein angiography(FFA)and optical coherence tomography(OCT).The selected patients were divided into group A and group B.The eyes in group A received intravitreal injection of conbercept 0.5mg/0.05 ml.The eyes in group B reintravitreal injection of either conbercept or ranibizumab,the best corrected visual acuity(BCVA),macular center retinal thickness(CMT)and intraocular pressure(IOP)of the patient`s eyes before treatment,and at 1w,4w,8w,and 12 w after treatment.Visual acuity tests were performed using a standard logarithmic visual acuity chart and the results were converted into a log MAR visual record.Results:There were 26 eyes in Group A,and 16 eyes in group B.Among them,the males have 13 eyes.The females have 29 eyes.The average BCVA(log MAR)of group A patients before operation was0.81±0.41,and the average BCVA(log MAR)of 1w,4w,8w,and 12 w after operation were 0.67±0.34,0.52±0.25,0.48±0.37 and 0.33±0.20,respectively.The BCVA(log MAR)was 0.86±0.34,and the average BCVA(log MAR)at 1w,4w,8w,and 12 w after operation was 0.77±0.33,0.55±0.21,0.43±0.17 and 0.55±0.21,respectively.After treatment,the BCVA in the two groups was significantly better than that before treatment,which was statistically significant(P <0.05).The comparison between the two groups showed no significant difference in BCVA changes after treatment(P>0.05).The average macular center retinal thickness of group A before treatment,1w,4w,8w,and 12 w after treatment were 554.3±207.5μm,364.9±158.7μm,317.2±151.5μm,248.5±52.2μm and 280.7±85.6μm.The average macular center retina thickness of group B before treatment,1w,4w,8w,12 w after treatment were 464.7±155.8μm,287±53.2μm,276.0±59.9μm,248.4±40.1μm and 345.1±117.8μm.After treatment,the CMT of the two groups was significantly lower than that before the treatment,and the difference was statistically significant(P<0.05).There was no statistically significant difference between the two groups during the follow-up of CMT changes after treatment(P>0.05).No significant adverse reactions such as elevated intraocular pressure,vitreous hemorrhage,and thrombosis occurred in either group of patients.Conclusions:1.Intravitreal injection of conbercept and ranibizumab for macular edema secondary to retinal macular vein occlusion can improve optimal corrected vision and reduce retinal thickness in the center of the macula.2.There was no significant difference between the two drugs in improving the best corrected visual acuity and reducing the thickness of the retinal center of the macula,and there were no significant complications.